Non-invasive Prenatal Diagnostic Validation Study



Status:Completed
Conditions:Other Indications
Therapuetic Areas:Other
Healthy:No
Age Range:18 - Any
Updated:5/27/2013
Start Date:September 2011
End Date:December 2012
Contact:Sallie McAdoo, MS
Email:smcadoo@natera.com
Phone:650-249-9090

Use our guide to learn which trials are right for you!

Development of Non-invasive Prenatal Diagnostic Test Based on Fetal DNA Isolated From Maternal Blood


The primary purpose of this study is to collect maternal blood samples from pregnant women
to develop a non-invasive prenatal diagnostic test based on fetal DNA isolated from maternal
blood.


The investigators will seek to enroll subjects to collect the following types of samples:

- Up to 2,000 maternal blood samples along with their corresponding paternal blood,
buccal or saliva samples (1,000 required for final analysis).

- Up to 200 maternal blood samples from carrying a fetus with a confirmed chromosomal
abnormality or genetic disorder, along with their corresponding paternal blood, buccal
or saliva samples (50 required for final analysis). For women who opted for
termination, a genetic sample of the fetus may also be collected.

- Up to 1,000 buccal or saliva samples from paternal grandfathers and/or the biological
father's brothers.

- Up to 1,000 cord, buccal or saliva samples from the born children.

- Up to 40 blood samples (20 non-pregnant females and 20 males) from healthy volunteers
(20 required for final analysis)

- Up to 400 blood samples from women undergoing D&C procedure following a miscarriage
along with corresponding paternal blood (or buccal or saliva samples) (200 required for
final analysis).

Inclusion Criteria:

- Pregnant women who volunteer to donate blood sample during the first -, second-
and/or third trimester

- The biological father of the child (or the father's brother and/or father) has to be
at least 18 years of age and consent to his blood, buccal, or saliva collection.

- Pregnant women whose fetus was diagnosed with a chromosomal abnormality or genetic
disorder by either amniocentesis or chorionic villus sampling who volunteer to
donate a blood sample.

- Pregnant women who volunteer to donate a blood sample after their spontaneous
miscarriage prior to undergoing D&C procedure and who choose to utilize Natera's
commercial products of conception molecular karyotyping service.

- Healthy volunteers (non-pregnant female and male) who volunteer to donate their blood
sample.

- Umbilical cord blood or cheek swab/saliva samples from born children o Pregnant women
who have participated in donating a blood sample during their pregnancy have the
option to donate either an umbilical cord blood sample after child delivery, or a
cheek swab or saliva sample from the born child using Natera's home kit.

Exclusion Criteria:

- Women carrying multiples
We found this trial at
1
site
Redwood City, California 94063
?
mi
from
Redwood City, CA
Click here to add this to my saved trials